Apex Molecular Ltd appoints Dr Jason Tierney as a Medicinal Chemistry Consultant

Apex Molecular Limited announces the appointment of Dr Jason Tierney as a medicinal chemistry consultant to work on their external customer medicinal chemistry drug discovery projects.

Jason is an experienced Drug Hunter, having over 25 years’ experience in Drug Discovery, both with Pharma (GSK and Organon), large Contract Research Organisations (CROs) (Charles River Discovery and BioFocus), Biotechs (Anima Biotech), MedChemica and Consultancy.

Jason has experience working in multiple therapeutic areas, including neuroscience, oncology, analgesia, pulmonary fibrosis and rare diseases. His expertise includes working in continually emerging new modalities, such as RNA therapeutics and PROTACs. Jason has been a successful innovator and co-inventor delivering multiple pre-clinical and clinical drug candidates, which have included AZD0780 (small molecule PCSK9 inhibitor acquired from Dogma Therapeutics by AZ now in Phase 2), a small molecule V1aR antagonist at Neumora Therapeutics acquired from BlackThorn Therapeutics (now in Phase 1), Org28611 at Organon (first water soluble CB1 / CB2 agonist analgesic, which went to Phase 3) and novel pre-clinical candidate RNA translation modulators at Anima Biotech for IPF and oncology. He is a named inventor on 13 patents and authored >10 peer-reviewed publications and reviews.

Apex Molecular recognises the market driven need for medicinal chemistry drug design and project management within their portfolio and wider sector. In addition to Apex Molecular’s expertise in complex organic synthesis and fundamental understanding of drug discovery, the incorporation of medicinal chemistry expands Apex Molecular’s services in new molecule design and data analysis to accelerate the “Design-Make-Test-Analysis (DMAT)" cycles to support customers in their research projects from target to novel leads and pre-clinical drug candidates.

Stuart Brown Apex Molecular’s CEO commented, ‘Customers and potential customers are increasingly requesting medicinal chemistry drug discovery services for their projects with us, and appointing Jason to the role of medicinal chemistry consultant is a natural step in evolving our services offering to the sector. We anticipate that this will open the door to new opportunities and customers for Apex Molecular and continue our company growth and development.’

Jason Tierney added, ‘I am relishing the opportunities to contribute my medicinal chemistry expertise and work with Apex Molecular’s experienced synthetic chemistry teams, customers and potential customers to deliver success projects and novel drug therapeutics, which will facilitate the company growth of Apex Molecular.’